期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

冠状动脉造影联合FFR在冠心病介入治疗中的价值 被引量：2

下载PDF
导出
摘要 目的分析冠状动脉造影联合心肌血流储备分数（FFR）在冠心病介入治疗中的应用价值。方法将2011年1月~2013年12月确诊的60例冠心病患者作为观察对象,随机分为观察组和对照组,每组30例。观察组患者行心肌FFR测定,当FFR≤0.8时,植入药物洗脱支架,术后给予支架内球囊后扩张;对照组患者行经皮冠状动脉介入治疗,并常规植入药物洗脱支架,比较两组患者的住院费用、不良事件发生率、病变个数、支架植入数目、心绞痛再发生率等。结果观察组植入支架数目及住院费用低于对照组,差异有统计学意义（P〈0.05）;两组观察对象术后6个月再发心肌梗死和再次血运重建等心脏不良事件发生率及心绞痛发生率差异无统计学意义（P〉0.05）。结论冠状动脉造影联合FFR在冠心病介入治疗中可减少医疗费用、减少支架使用数量,且随访6个月后不增加患者心脏不良事件发生率及心绞痛发生率。
作者 卢辉耀
机构地区 福建医科大学附属第二医院
出处 《海峡药学》 2014年第8期86-88,共3页 Strait Pharmaceutical Journal
关键词 冠状动脉造影 心肌血流储备分数 冠心病
分类号 R969.4 [医药卫生—药理学]
  • 相关文献

参考文献13

二级参考文献169

  • 1刘菁晶,王志坚,林文华,史宏岩,任自文.替罗非班引起严重血小板减低1例[J].临床荟萃,2006,21(10):747-747. 被引量：11
  • 2杨海鹰,李崇剑,尤士杰,阎秀英,赵新然,秦学文.替罗非班引起急性血小板减少一例[J].中国循环杂志,2006,21(5):367-367. 被引量：4
  • 3Ahmed I, Majeed A, Powell R. Heparin induced thrombocyto- penia : diagnosis and management update. Postgrad Med J, 2007, 83(983) : 575-582.
  • 4Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curt Hematol Rep, 2004, 3(2): 143-147.
  • 5Bougie DW, Wilker PR, Wuitschick ED, et al. Acute throm- bocytopenia after treatment with tirofiban or eptifibatide is associa- ted with antibodies specific for ligand-occupied GPIIb/IIIa. Blood, 2002, 100(6) : 2071-2076 .
  • 6Said SM, Hahn J, Schleyer E, et al. Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol, 2007, 96(2) : 61-69.
  • 7Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors : position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost, 2006, 4(3) : 678-679.
  • 8Billheimer JT, Dicker IB, Wyrm R, et al. Evidence that throm- bocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood, 2002, 99(10): 3540-3546.
  • 9Moses JW, Stone GW, Nikolsky E, et al. Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. J Am Coil Cardiol, 2006, 47:2164-2171.
  • 10Pijls NH,van Son JA, Kirkeeide RL, et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation, 1993, 87:1354-1367.

共引文献145

同被引文献33

  • 1张培,傅国胜.血流储备分数在冠心病介入治疗中的指导作用[J].国际心血管病杂志,2007,34(1):40-43. 被引量：1
  • 2Gould KL,Johnson NP,Bateman TM, et al. Anatomic versus physiologic assessment of coronary artery disease. Role ofcoronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision- making[J]. J Am Coll Cardiol, 2013,62 (18) : 1639-1653.
  • 3Johnson NP,T6th GG, Lai D, et al. Prognostic value of frac tional flow reserve: linking physiologic severity to clinical outcomes[J]. J Am Coll Cardiol,2014,64(16) : 1641 -1654.
  • 4Pijls NH, van Son JA, Kirkeeide RL, et al. Experimental ba sis of determining maximum coronary, myocardial, and col lateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty [J]. Circulation, 1993, 87 (4): 1354- 1367.
  • 5Glaser R, Selzer F , Faxon DP ,et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention [J ]. Circulation, 2005, 111 ( 2 ) : 143- 149.
  • 6Pijls NH,De Bruyne B,Peels K, et al. Measurement of frac tional flow reserve to assess the functional severity of coro nary-artery stenoses [J]. N Engl J Med, 1996, 334 (26): 1703-1708.
  • 7Kolh P,Wijns W, Danchin N, et al. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myo- cardial revasculariation[J]. Eur J Cardiothorae Surg, 2010,38 (Suppl) : S1-S52.
  • 8Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/ AHA/SCAI guideline for percutaneous coronary interven- tion: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascu- lar Angiography and Interventions[J]. Catheter Cardiovasc Interv,2012,79(3) :453 -495.
  • 9Pijls NH,van Schaardenburgh P,Manoharan G, et al. Percu taneous coronary intervention of functionally nonsignificantstenosis:5-year follow-up of the DEFER Study[J]. J Am Coil Cardiol,2007,49 (21) :2105-2111.
  • 10Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused up dates: ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronaryintervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2009,54 (23) : 2205-2241.

引证文献2

二级引证文献7

海峡药学
2014年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部